AWM
LGND icon

Avior Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Avior Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-79
Closed -$5.77K – 3066
2024
Q1 		$5.77K Buy
+79
New +$5.82K ﹤0.01% 2040
2023
Q3 		– Sell
-40
Closed -$2.88K – 1644
2023
Q2 		$2.88K Hold
40
– – ﹤0.01% 1311
2023
Q1 		$2.94K Buy
+40
New +$2.84K ﹤0.01% 1343

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Avior Wealth Management's LGND Position: Q2 2024 in Review

Avior Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 79 shares — an estimated $5.77K sold.

Avior Wealth Management first reported a position in LGND in Q1 2023 and held it in 3 quarters. The position peaked at $5.77K in Q1 2024. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Avior Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 79 Ligand Pharmaceuticals shares in Q2 2024, an estimated $5.77K.
  • Avior Wealth Management first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Avior Wealth Management's Ligand Pharmaceuticals position peaked at $5.77K in Q1 2024.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.